Aphexda approved in US to improve autologous stem cell transplants
The U.S. has approved BioLineRx’s Aphexda (motixafortide) in…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreThe U.S. has approved BioLineRx’s Aphexda (motixafortide) in…
Some multiple myeloma cells acquire mutations that allow…
Blood Cancer Awareness Month, observed globally every September,…
The U.S. Food and Drug Administration (FDA) has granted…
Nanjing Leads Biolabs is planning to launch a…
Researchers at Tel Aviv University in Israel have developed…